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1. Introduction  
New scientific developments, such as molecular editing techniques (e.g. zinc finger nucleases) and enhanced 
ways of introducing modifications (e.g. lentiviruses), are leading to an increasingly extensive range of potential 
GM animal applications. Proponents of GM animal production argue that some of these applications should be 
integral to the development of new diagnostic techniques and drugs for human diseases, through the production 
in animals of novel replacement proteins, vaccines, research models and tissues for the treatment and prevention 
of human diseases (COGEM 2011). They also propose that GM livestock have the potential to contribute to 
improving the environment and human health, with consumption of fewer resources and reduced waste 
production (Murray and Maga 2011). GM developments could also improve the welfare of animals by reducing 
disease incidence and enhancing overall health and well-being, minimising the need for care intervention (Kleter 
2010; Maga and Murray 2010).  
From an extensive survey we have identified over thirty GM animal applications under development or already 
in the market around the world, although this is likely to be an underestimate as some developments may not 
have been published. These data should therefore be considered illustrative. Most GM animals are currently 
used for research, for example to study mechanisms of gene action and function, or to test or produce new 
therapeutic agents. Commercial applications of GM animals include use as bioreactors to produce recombinant 
pharmaceutical proteins in milk, for example ATryn® (for blood clotting) and Ruconest™ (Rhucin® in non-
European territories) to reduce acute swelling (Houdebine 2009;Vàzquez-Salat 2012) and potential use in 
xenotransplantation (the transplantation of cells, tissue or organs from one species to another) (Niemann et al. 
2009; Ekser et al. 2012). There are currently no known GM animal food products on the market, but a faster 
growing GM salmon (AquAdvantage®) has been under regulatory review in the US since 1993 (Van 
Eenennaam and Muir 2011). Other animals have been modified to increase their growth rates and improve the 
quality of animal products (Marshall et al. 2006; Hume et al. 2011) including reducing the level of human 
allergens such as β-lactoglobulin (Jabed et al. 2012).  
Pigs with a reduced environmental footprint (Golovan et al. 2001) were developed in Canada (EnviropigTM) and 
were proceeding through regulatory approvals, although work on this has now reportedly ceased (Pig Progress 
2012). China is said to have a major agricultural GM program to make more animal-based food available 
(GAIN 2011) and scientists in Africa are aiming to produce GM cattle resistant to sleeping sickness (Noyes et 
al. 2011). In the UK, scientists are developing GM chickens resistant to avian influenza (Lyall et al. 2011). GM 
animals have also been used to produce spider silk for medical and defence purposes (Lazaris et al. 2002; 
Service 2002), but this process was reportedly replaced by production from cells in culture (COGEM 2011). 
Another application involves GM insects produced to reduce spread of malaria and dengue fever to humans 
(COGEM 2011). Applications predominantly restricted to laboratory use or for the pet market (fish with 
enhanced colour range (Pray 2008)) are not considered in this paper. This wide range of applications in a 
number of species represent a diversity of different contexts, both natural and social.  
Food security concerns are arising from a combination of population growth, impacts of climate change on 
weather, and competition for scarce resources, including water and energy. Global aggregate food production is 
projected to increase 60% between 2005/7 and 2050 to meet demand (Alexandratos and Bruinsma 2012, p7). At 
the same time, agriculture will need to adapt to the impact of climate change and will likely be expected to 
contribute to reducing greenhouse gas emissions (Garnett 2009). Greater and more frequent threats from plant 
and animal diseases are expected as climate change allows the spread of vector-borne diseases into new areas 
(Tomley and Shirley 2009) and these will be allied to changes in consumption patterns - the world demand for 
meat and milk is projected to more than double by 2050 (FAO 2009). China already consumes more than 25 
percent of all the meat produced worldwide (Subramanian 2012), having increased from 8 million tonnes in 
1976 to 71 million tonnes in 2012 (now more than double that in the US). These trends are leading to calls for 
‘sustainable intensification’ of agricultural production (Foresight. The Future of Food and Farming 2011). It has 
been argued that GM animals could contribute greatly to meeting these challenges (Fahrenkrug et al. 2010; 
Hume et al. 2011). 
Over sixty percent of the GM animals that we have identified as potentially for commercial application have 
been developed to produce pharmaceutical proteins or to be disease resistant. This suggests that these two 
categories are currently the most commercially attractive propositions, possibly because they could be 
considered less controversial than other applications. Sixty five percent of the GM animal applications we 
identified appear to be at advanced research stages and 25% are either in the approval process or have been 
approved for commercialisation (mostly in the pharmaceutical sector) (Figure 1). However, it is too early in the 
development of this technology to predict where the greatest economic and societal benefits will arise and which 
currently attractive applications of GM animals will be superseded by new production processes or even better 
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products. Some sectors, such as the pharmaceutical sector, may prove to be less controversial and develop more 
readily. 
This paper considers the new scientific techniques that are enabling the development of GM animals, 
particularly for food and agriculture-related purposes, and examines the relevant regulatory approaches adopted 
particularly in the European Union (EU). The nature of the regulatory framework will determine companies’ 
and nations’ ability to benefit from these new innovative approaches to animal production, and we explore the 
potential innovation-related impact of current regulatory choices. This paper builds on our interdisciplinary 
expertise over two decades of following the development of GM technologies and the regulation of 
biotechnologies, supplemented by an extensive literature review of current developments worldwide. We 
synthesise findings from multiple research projects involving prolonged interaction with over 20 informants in 
research, regulation and industry and participant observation in industrial and regulatory meetings. 
 
2. Scientific developments in GM animal production 
Scientific research to develop GM animals has been ongoing since the early 1980s and now a range of new more 
precise techniques is offering opportunities for easier, more cost-effective and efficient generation of GM 
animals. These techniques differ in their suitability for different animal species, their efficiency of 
transformation, and their implications for risk assessment.  
As shown in Figure 2, methods for introducing a genetic modification have evolved from microinjection into an 
early embryo (Gordon et al. 1980; Palmiter et al. 1982), through modification of cells in culture for subsequent 
re-introduction into an early embryo, to using viral vectors (such as lentiviruses) to introduce modified genes 
into a large number of cells, either in culture or in an embryo. Molecular techniques to manipulate the genetic 
material itself have evolved from inserting single genes (usually in combination with marker genes to allow the 
introduced gene to be identified) to manipulating individual nucleotides.  
The original method, the injection of DNA coding for a specific novel trait into the nucleus of a fertilised egg 
(Clark and Whitelaw 2003; Ittner and Gotz 2007), is technically difficult and inefficient and only around 1 per 
cent of the treated embryos result in live GM animals (Le Provost et al. 2009). The expression of the novel gene 
also varies significantly as the technique is not able to target introduction of the gene to a precise location in the 
genome, or to control the number of copies introduced (Dove 2000). Thus, whilst conventional micro-injection 
based methods are successful in generating transgenic animals, the search for more efficient and more 
accurately targeted approaches has continued (Park 2007).  
Nuclear transfer technology (cloning) was developed to overcome some of the technical issues with micro-
injection by genetically modifying cells in culture, identifying cells that had been successfully modified and 
using these to develop GM animals (Suk et al. 2007; Buck 2011). In 1997, the first GM animal was produced in 
this way (Schnieke et al. 1997) but this technique is technically demanding and costly in comparison to other 
approaches (CAST 2009). Nuclear transfer has changed the timing and location of genetic modification from the 
early embryo to cell culture, and allowed selection of cells only with successful genetic modifications to be used 
to produce the animal.  
Dramatic improvements in the efficiency of GM animal production took place in the early 2000s based on 
developments in human gene therapy. The use of lentiviruses instead of micro-injection to deliver genetic 
material allowed manipulation of both cell cultures and well-developed chick embryos (McGrew et al. 2004). 
According to Novosleva et al. (2007) using the standard microinjection procedure, between 1-5% of injected 
eggs gave rise to a transgenic founder animal, whereas through the use of lentiviral vectors, over 30% of the 
injected eggs resulted in a transgenic founder animal. An alternative method used to introduce new genetic 
material, drawing on developments in human fertility treatment, particularly the use of intra-cytoplasmic sperm 
injection (ICSI), is GM sperm injected directly into the egg (Kaneko et al. 2005).  
Molecular methods of manipulating genetic material have also improved substantially with the ability to 
suppress the expression of existing genes. Most notably, RNA-interference (RNAi) has been used to regulate or 
prevent the expression of a gene resulting in chickens that are unable to transmit avian influenza (Lyall et al. 
2011) and a range of other opportunities (Clark and Whitelaw 2003). 
Additional methods for targeting modifications to a specific location in the genome include, in combination with 
nuclear transfer, homologous recombination of the introduced DNA fragment in donor cells, usually involving a 
selection marker (Cappechi 1989). More recently the ability to ‘edit’ DNA using a range of synthetic enzymes 
(nucleases) that act as molecular ‘scissors’ has further improved the capabilities of genetic technologies: (i) zinc 
finger nucleases (ZFNs) with each zinc finger targeting specific nucleotide triplets; and (ii) a group of nucleases 
created from Transcription Activator-Like Effectors (TALENs) with each TALE targeting individual 
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nucleotides in specified locations in the genome (Durai et al. 2005; Geurts et al. 2009; DeFranceso 2011; 
Carlson et al. 2012). Both ZFNs and TALENs and an even more recent RNA system known as CRISP-Cas 
(Wang et al. 2013) cause user-specified breaks in the DNA, and as the break is repaired small mutations or other 
changes readily occur at the desired site, either resulting in deactivation of the gene, or allowing new genetic 
material to be added. For example, a pig model of human familial hypercholesterolemia, to investigate 
predisposition to heart attack at an early age, is being developed using TALENs to knock out the relevant gene 
(Carlson et al. 2012), currently achieving 10-20% success rates in editing the founder population (Whitelaw, 
unpublished data).  
Where is development of GM animals being funded? There are few publicly available data on research 
expenditure in the commercial GM animal sector. In the public sector, the low level of funding to support the 
development of GM animals in some jurisdictions has been criticised (Fernandez and Schook 2005; COGEM, 
2011) and the US, UK, Australia and New Zealand are alleged to have gradually reduced public funding for this 
technology. Where public funding in the US and EU is available, the main focus is said to be on the 
environmental safety of GM animals.  
A different scenario is occurring in emerging economies where public statements suggest heavy investment in 
research and development on GM animals. Taking China as a case in point, GM technology is part of the 
government’s vision for food security. The government is the primary investor, having developed an extensive 
research programme to improve disease resistance in animals, produce valuable compounds and increase 
productivity (GAIN 2011; Yang et al. 2011). Publicly funded research institutes or universities have developed, 
or are researching, GM animals, but no arising technologies are known to be in commercial production. The first 
applications are expected to reach the market in two years (Yang et al. 2011; Yang, 2003). For example, the 
Heilongjiang Fishery Institute of Chinese Academy of Fishery Science has developed GM carp using a growth 
hormone gene, reported to be under field trial, and Shanghai Genon Nio-engineering has developed GM goats 
that express either a human lactoferrin or a lysozyme gene. The former has been approved for an enlarged field 
trial and the latter is under restricted field trial (GAIN 2011). More recently, scientists in China have used 
somatic cell nuclear transfer to demonstrate improvements in milk yields from cattle (Yang et al. 2011). The 
Chinese government has also invested in large scale research institutions and complexes including China 
Medical City in Taizhou, a national high-tech pharmaceutical park that includes research and development on 
GM animals and the Institute for Animal Science, dedicated to the development of GM cattle (Fernandez and 
Schook 2005).  
In summary, the new genetic techniques that have emerged since 2000 have the ability to modify animals more 
easily and precisely and in many cases more cheaply. The modifications produced are more nuanced in nature, 
with much higher success rates and the increased range of possibilities for manipulating the genome of animals 
has increased scientific and commercial interest with much more significant investment in emerging than in 
developed economies. Where development is slow compared to the potential, this is at least partly related to the 
current state of regulatory systems, as discussed in the next section.  
3 Regulatory issues in GM animal development and commercialisation 
Regulatory systems are among the most important influences in determining the course of technological 
innovation. This is true in terms of which products can be developed safely, the type and size of companies able 
to commercialise new technology, and which nations and regions are able to prosper based on locally generated 
knowledge (Mittra et al. 2011). Until 2008 there appeared to be no serious impetus behind regulatory initiatives 
related to GM animals, but the prospect of some applications being market-ready has since stimulated activity 
on safety assessments internationally. 
3.1 The International Context 
International trade in food products are subject to regulation in the context of the Cartagena Biosafety Protocol 
and the World Trade Organization (WTO) agreements. The Cartagena Biosafety Protocol applies to Living 
Modified Organisms, including GM animals, and is intended to protect biodiversity.  International regulatory 
guidance on GM animals within the WTO is given under the Codex Alimentarius (2008) building on the 
regulatory precedent of GM plants and microorganisms. In many cases it will not be appropriate to translate a 
regulatory approach developed for a different set of organisms directly across to GM animals. For example, the 
introduced DNA and/or derived products may impact either positively or negatively on the health status of the 
animals. GM animals may have either a greater or a lesser tendency to accumulate specific toxic substances or 
zoonotic pathogens that could be transmitted to consumers. This variability in potential impact leads to 
recommendations for a case-by-case approach to the regulation of GM animals, although the presumption in the 




Regulations are in place for GM animals in the USA (FDA 2009), Canada (Health Canada 2011) and Australia 
(AFAA 2004). In India a bill has been drafted to create the Biotechnology Regulatory Authority to be 
responsible for assessing all GM animal related applications (Vàzquez-Salat et al. 2010). Argentina has 
developed a case-by-case regulatory regime and was the first country in Latin America to develop two 
generations of GM cows capable of producing human growth hormone (Salamone 2006). Brazil also has 
introduced a Biosafety Law to regulate GM techniques (Mendon et al. 2008). As noted above, there are also 
strong emerging developments in China (Huang and Wang 2002; GAIN 2011). 
One of the most important international issues in regulation of GM technologies continues to be differences in 
regulatory approaches focused primarily on the process by which new technology is developed, and those 
approaches focused primarily on the characteristics of the arising product. Europe (but not necessarily all its 
member states) is broadly seen as “process-based,” Canada uses novelty as the regulatory trigger and is 
primarily “product-based,” and the US is similarly product-based although technological process can have 
implications for deciding which regulatory pathway is appropriate. Although these differences emerged in the 
1980s (Tait and Levidow 1992), they remain a source of international tension underlying, for example, US and 
EU trade disputes about GM crops that were heard by the WTO (WTO, 2010). Although there is a tendency to 
see the product-based approach as less antagonistic to innovation than the process-based approach, in practice 
both have their problems (Mandel 2004), and the differences between the approaches can be over-emphasised to 
make points about issues extending beyond the operations of regulatory authorities. Irrespective of whether a 
product or process-based approach is taken, there may be more fundamental presumptions to address first, 
namely the perception that GM animals raise more serious human risks than GM plants, and pose more 
significant environmental risks in light of their mobility and hence potential for invasiveness (Waigmann et al. 
2012).  
 
3.2 European Regulatory System 
GM organisms used for food or feed in the EU are regulated through a centralised process governed by key legal 
instruments (EU Directive 2001/18/EC and Regulation (EC) 1829/2003). Processes for approval are built on a 
comparative approach that aims to identify biologically relevant differences by comparing the Genetically 
Modified Organism (GMO) with a non-GM counterpart. A GM animal may, however, need to be evaluated 
where there is no conventional counterpart. The European Food Safety Authority (EFSA) is the body charged 
with providing independent scientific advice to the European Parliament, European Commission and Member 
States on the basis of risk assessments related to food and feed safety, including risks related to the use of 
GMOs (plants, food animals and micro-organisms). In the case of GM animals, the relevant EFSA Guidance 
Document proposes the use of non-GM surrogates with similar characteristics, and the need for containment in 
the experimental environment. The Guidance Document will contain separate sections relevant to fish, insects 
and terrestrial mammals and birds, with case studies (Waigmann et al. 2012). 
In 2011, to pre-empt marketing of food from GM animals before legislation was developed, the European 
Commission asked the EFSA to assess the possible risks for food and feed safety and for the environment, and 
also issues related to animal health and welfare (Bronzwaer 2008; EFSA 2012; EFSA 2013). As Vàzquez-Salat 
et al. (2010) note, disagreement persists over the application of EU GMO regulations at member state level, 
given that animal welfare is of higher political importance in some EU countries than in others. In the 
Netherlands and Denmark, GM animal regulation includes specific regulations on the ethical aspects of GM 
animal production. In the Netherlands, a political party with animal rights as their highest priority (The Party for 
the Animals) has parliamentary representation and national regulation includes the ethical principle that genetic 
modification of animals involves ‘erosion of the species identity’ and should only be permitted in the service of 
an application of substantial importance, e.g. medical uses but not food production (COGEM 2011). Apart from 
GM animals for pharmaceutical production, the regulatory regime in the EU remains untested with respect to 
other applications of GM animal technology. 
There are several regulatory challenges in translating the EU GM crops regulatory approach to a system adapted 
to GM animals, such as the additional aspect of animal welfare, mobility and the status attributed to animals. As 
it stands, the existing GM crop regulation is itself under challenge due to developments in molecular biology 
which are pertinent to both crops and animals. For example, whereas GM animals produced by micro-injection 
or random insertion in nuclear transfer donor cells can be identified through the presence of the inserted gene 
construct with or without the presence of a marker gene, the same cannot be said for changes caused by genome 
‘editors’. In particular, TALENs and ZFNs may produce a change consisting of a single nucleotide, something 
that could be produced by a naturally occurring mutation and would therefore be difficult, if not impossible, to 
identify as artificially induced. The question remains whether these types of alterations would be classed as 
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genetic modifications under the definitions of the EU Directive (Dunwell, personal communication; Lusser and 
Davies 2013). 
European governance of GM technologies, particularly where a product is likely to become part of a food chain, 
has been strongly influenced by political considerations, in which public opinion has tended to predominate over 
science-based risk assessment Vàzquez-Salat et al. (2012). Although the advice of the EFSA is scientifically 
based and may conclude that there are no significant risks associated with the use of a particular GMO, the 
political process into which this advice is injected has so far been able to prevent commercial application of the 
technology for GM crops. Policy makers operate on a presumption that European public reactions to GM crops 
will be negative and this is a major political consideration for several national governments with strong Green 
party representation, but may not fully reflect public attitudes as these can change with time (e.g. Gaskell et al. 
2011). The intention to base regulatory systems for GM animals on the GM crop precedent could imply a 
continuing influence of political considerations rather than a decision process based on evidence of risks and 
benefits (Tait and Barker 2011; Vazquez-Salat and Houdebine 2013).  
4 Regulation/Innovation Interactions 
We have previously explored the nature of the relationships between innovation and regulation across a broad 
spectrum of life sciences (Milne and Tait 2009; Tait and Barker 2011; Mittra and Tait 2012; Mastroeni et al. 
2013). We have demonstrated how regulation has implications not only for ensuring the safety and efficacy of 
the product being brought to market, but also for individual company strategies, for the type of firm that will be 
successful in bringing the products to market, and for the ability of an entire sector to contribute to national and 
regional economic development, as summarised in the following examples.  
(i) The lengthy and costly regulatory system for drug development that has been built up over the past 
fifty years has generally favoured multinational companies (MNCs) in that it acted as a barrier to entry 
for new entrants, with the result that the sector is dominated by the innovation strategies of these 
MNCs (Tait et al. 2008; Mittra et al. 2011). Both regulators and industry increasingly recognise that 
this regulatory system is now so onerous that it is leading to failures in development of potentially safe 
and useful products and at least in the US ways are being sought to adapt the current regulatory 
systems to the opportunities presented by 21st century science (FDA 2011). 
(ii) When new developments emerge in life sciences, the choice of regulatory approach, usually at an early 
stage in the development of practical innovations, will determine which products can eventually reach a 
market place and what scale of company will be needed to commercialise the technology. Only large 
multinational companies (MNCs) will be able to support the high levels of investment over long 
timescales required to commercialise most life science products, forcing all other innovators to work 
with the innovation strategies of the MNCs (Tait et al. 2008). Thus, the choice by the US Food and 
Drugs Administration (FDA) and the European Medicines Agency (EMA) to develop the 
pharmaceutical regulatory system  as the appropriate model for both cell therapies (Tait 2007; 
Mastroeni et al. 2012) and novel diagnostic technologies (Mittra and Tait 2012) is likely to mean that 
only large MNCs will be able to develop products in these areas, to the neglect of smaller niche market 
opportunities and of more innovative products and processes that would have arisen from a small and 
medium sized enterprise (SME) component of the sector. 
(iii) Regulatory systems for GM crops provide another example of how an early choice of regulatory 
system will determine the future trajectory of a technology. In the 1980s, the choice of regulatory 
systems being considered for GM crops was between treating them as a new plant variety or as a new 
form of crop protection technology. The choice of the latter regulatory approach shifted the innovation 
trajectory from seed companies to agrochemical MNCs, with a different set of choices for first 
generation products, leading eventually to take-over of seed companies by the agrochemical MNCs and 
contributing to the negative public framing of the technology in Europe. For example, Monsanto 
embarked in the 1990s on a very expensive strategy of ‘buying the route to market’ (Chataway et al. 
2004). The subsequent precautionary regulatory approach in Europe has failed to adapt to evidence of 
the safety and the benefits of these products and has led to a serious decline in innovation in GM crops 
directed to European agricultural systems (Tait 2008; Tait and Barker 2011). 
As noted earlier sixty five percent of the GM animal applications identified in this review are at advanced 
research stages but companies do not seem to be pushing towards commercialisation (Figure 1). Potentially 
revolutionary scientific developments could create valuable opportunities in new innovative markets, but 
companies will be unwilling to invest in the new technologies while there is uncertainty about the nature of 
future markets, with the ambivalence of policymakers towards GM animal applications and with no clear 
regulatory path, Fernandez and Schook (2005 p6) observe: 
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“…. between uncertain consumers and an unclear regulatory pathway, animal biotechnology finds 
itself at a crossroads. Will it simply stay where it is for the foreseeable future, idling but not 
progressing? Will it go forward to its logical destinations—such as agriculture and drug markets—or 
turn around and retreat the way it came, … a research tool that …. never ventures out to the farm or 
pharmaceutical factory? … will other countries developing animal biotechnology simply take the 
wheel and drive ahead, putting their own transgenic and cloned animal products on the market?” 
In the absence of applications for commercial release in the EU, what can be learned from market authorisation 
processes in other jurisdictions? In an example of this process at work, in the late 1990s a line of GM pigs with 
the capability to digest plant phosphorus more efficiently, the EnviropigTM, was developed at the University of 
Guelph, Canada, (Golovan et al. 2001). EnviropigTM reached the initial stages of the Canadian marketing 
authorisation procedure, but after more than a decade of interacting with regulators, in April 2012 Ontario Pork, 
one of the project’s funders, decided to withdraw (Pig Progress, 2012). The EnviropigTM might have been the 
more elegant technological solution, but inorganic phosphate feed additives address the nutritional demands of 
pigs, whereas feed supplementation with phytase makes organic phosphate bioavailable and to an extent lessens 
phosphorus excretion. This illustrates the complex interactions between innovation and regulation: regulatory 
uncertainty made it impossible for the developer to assess the relative commercial advantage of the new 
technology, and the long time lag between proof-of-concept of the technology and approval for commercial 
applications introduced delays and uncertainties that made it unlikely that the modified pigs would be tested in 
the market.  
A second example demonstrating the impact of regulatory delays and uncertainties on innovation is 
AquAdvantage® Salmon, being developed in the USA, that has been in a regulatory review process for over 15 
years. The underlying brood stock are conventional farmed Atlantic salmon varieties, modified using pronuclear 
injection techniques, adding a growth hormone regulating gene from a Pacific Chinook salmon and a promoter 
from an ocean pout, to enable it to grow all year-round, instead of only during spring and summer. 
AquAdvantage® Salmon are claimed to reach market size twice as fast and to reach a mature size faster than 
traditional salmon without increasing in size, making them indistinguishable in appearance to conventional 
farmed salmon. Although they are bred to be sterile by pressure-induced triploidy, concerns about fish escapes 
have suggested to some that open water net pens should be replaced by either hard form floating containers, or 
on-land wholly contained facilities (Van Eeneennaam and Muir 2011).  
When AquaBounty Technologies, the developer of AquAdvantage® Salmon, sought regulatory guidance from 
US Food and Drugs Administration (FDA) for its development and approval in 1993, no regulatory pathway 
existed for GM animals. The company petitioned for regulation under the FDA as they thought that this rigorous 
pathway for approval would help assuage public concerns regarding food from GM animals. AquaBounty 
Technologies submitted the first data set to the FDA in 1996 and 40 US Senators and Representatives wrote to 
the FDA requesting that it reject the application. The FDA continued to review the application to approve GM 
salmon or AquAdvantage® Salmon as the first genetically modified animal to be introduced into the United 
States food supply, and in September 2010 an FDA advisory panel indicated that the fish was generally safe 
(Van Eenennaam and Muir 2011). Since then high-level policy issues have further delayed formal approval of 
the modified salmon. In December 2012, the US FDA (2012) announced a preliminary finding that (p 5) “… an 
approval of this application … would not have a significant impact on the US environment”. Subsequently, 
following a consultation period extended to April 26th 2013, final approval is still on hold in a process that has 
similarities with the interactions around scientific risk assessment by the EFSA and the politics of the European 
Parliament in the approval process for GM crops.  
It is not unusual for the first applications of a novel technology to take a considerable time to obtain regulatory 
approval (for example Martineu (2001) traces the steps between 1990-94 to gain regulatory approval for one of 
the first GM crops, Calgene’s Flavr Savr ™ tomato in the USA). It is also possible that these applications are 
considered more controversial than other applications. Nevertheless, time to market, combined with regulatory 
costs and uncertainties in the process, create serious challenges for technology developers that are likely to 
restrict the type of developer and the number of developers willing to invest in GM animal production. 
Difficulty in obtaining financial investment will particularly discourage smaller companies or public sector 
organisations, perhaps with more innovative applications, from entering these markets. Venture capitalists, in 
this as in other areas, tend to invest in technologies with clearer regulatory pathways to minimise costs, delays 
and uncertainties. By contrast, technologies that depend on breaking new regulatory ground can strand capital if 
they never reach the market, or if they do, they might be out-dated by the time they are approved. Most GM 
animals currently being developed in advanced economies are in university spin-off companies or small and 
medium enterprises that are unlikely to be able to negotiate a lengthy and costly regulatory process the outcome 
of which is uncertain.  
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Difficult regulatory environments in Europe and North America are thus likely to lead to research and 
development on GM animals moving to jurisdictions that are more favourable to development (COGEM 2001). 
For example, a project to manufacture anti-diarrhoea medicine from GM goats that express the human enzyme 
lysozyme in their milk (Murray et al. 2010), was transferred to Brazil in 2010 after 10 years of research in the 
US. Brazilian scientists have received $3.5 million from their government to initiate human trials of the goats’ 
milk, whereas in the US the project received a $400,000 grant from US Department of Agriculture over three 
years for a study focused on the environmental safety of the GM animals. The decision to relocate the project 
was partly influenced both by the lack of funding and by the delay of more than 10 years by the US FDA in 
deciding how to regulate GM animals. The FDA issued guidance to those developing the product in January 
2009 by which time they were already in discussions with colleagues in Brazil. Given successful human trials, 
the GM goat milk is expected to progress through the Brazilian approval process more smoothly and quickly 
than it would in the USA (Regaldo 2010).  
Decisions on location of company activities are complex but the above instance seems likely to become a 
pattern unless clearer regulatory approaches with defined and evidence-based routes to market are developed in 
Europe and the US. In these regions regulatory regimes for GM animals produce, to varying degrees, a negative, 
reinforcing cycle of regulatory inertia, lack of investment, policy ambivalence, lack of research funding and lack 
of commercial products. Increasingly sophisticated and discriminating innovation in the methods available for 
producing GM animals raises questions about the current weak state of development of regulatory regimes in 
the EU and USA; about the appropriateness of regulations that have been derived in the context of previous 
generations of GM technology; and about the relevance of regulatory systems developed for GM crops and 
micro-organisms to GM animals. Furthermore, the international nature of life science innovation processes 
means that challenges to regulatory systems seen as inappropriate in the EU and USA could lead to major 
regional differences in the rate and scope of innovation in novel technologies and, potentially, to poor 
consideration of benefit, risk and safety issues. 
5 A regulatory framework for GM animals 
 
5.1 Innovation configurations as a basis for a regulatory framework 
GM animals present complex and interacting problems for both innovators and regulators, in common with 
many other areas of life science innovation. The main problem with innovation-regulation interactions in the 
context of GM animals might lie in the apparent reluctance of policy-makers to engage in the development of 
regulations specific to GM animals. Falling back on GM crops as the appropriate regulatory precedent for GM 
animal developments might help to set part of the framework, but divergences in the regulation of conventional 
plants and animals already suggest that the differences between GM plant and animal regulation will outweigh 
the similarities. In addition, the technologies surveyed in this study suggest that caution needs to be exercised in 
using regulatory precepts and procedures developed for older technologies in the regulation of newer 
technologies. Given the small number of technologies for which commercial approval has been sought, it is 
unlikely that regulators will take the initiative. Yet to emerge is an integrated industry sector with the capacity to 
foster inter-organisational collaborations and a clear vision of the new, potentially path-breaking innovation 
portfolio it wants to develop a ‘configuration of innovators’ (Brown et al. 2001). This term ‘configuration’ 
captures the creation of a complex network of relationships among firms and between firms and key public 
constituencies. These can include the development of new institutional alignments, cultures, new ‘social’ 
markets and organisational resources. Although the Biotechnology Industry Organization and EuropaBio acts as 
advocates for industry, the concept, as described by Brown et al. 2001, extends beyond conglomerations of 
innovative companies. 
The kind of configuration advocated by Brown et al. could greatly facilitate the development of effective GM 
animal regulatory systems. Indeed, given the diversity of types of GM animals and of areas of application of the 
technology, it is likely that there will be several such potential configurations, each requiring different 
regulatory approaches. Future regulatory frameworks for GM animals will need to take account of the dynamics 
of each set of configurational relationships given, as we note above, that the regulatory system adopted will 
determine the nature of the innovative products developed, their areas of application, and the time-scales for 
their development. Without a prior set of visions driving coherent programmes of innovation and contributing 
actively to the development of regulatory systems for GM animals, there is a strong probability that the 
emergent regulatory systems will not be responsive to either path-breaking or incremental innovation. 
Innovation configurations that could build innovative momentum around animal bio-science developments 
could be based initially on the kinds of companies currently involved in producing the animals, as outlined 
below. These could then form the nuclei on which to build viable innovation configurations along with adaptive 
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regulatory approaches based on the markets for the products, and the risk and ethical issues raised by the 
innovations.  
(i) Poultry, pigs and dairy cattle 
The poultry and pig breeding sectors, and to some extent dairy cattle, are characterised by a high level 
of competition and a small number of dominant companies, with significant activity also from farmer 
co-operatives acting internationally. Where food uses are involved, food processing and distribution 
markets will be relevant. Individual farm businesses will also be key components of the value chain. 
Where there are health-related applications this may bring in large or small pharmaceutical companies 
either directly involved as breeders or as downstream processors and marketers of pharmaceutical 
products.  
(ii) Beef cattle, sheep and goats 
Breeding of animals in this sector in the EU is mainly in the hands of individual farmers or breeders or 
of farmer cooperatives, creating a challenge for the coordination activities required to bring together an 
effective innovation configuration. Depending on the type of innovation, the wider farming community 
will also need to be involved in downstream production as may food processors and distributors and 
also the health care sectors. This sector seems particularly unsuited for co-ordinating activities to 
promote development of GM animals. 
(iii) Insects and fish 
Insects and fish incorporating bioscience innovations are mainly produced by small and medium-sized 
Enterprises (SMEs). Without a well developed innovation configuration involving companies of a 
range of different sizes and influence, individual small companies in this area will struggle to be heard 
in debates about regulatory processes. 
Configurations within each of these sub sectors depends on a number of actors perceiving a specific GM animal 
application as being advantageous to develop. As yet there is little evidence of such intentions in several of the 
sectors. Configurations built on each of these three subsectors will encounter different regulatory challenges 
depending on whether, for example: they are selling products into the food or pharmaceutical sector; the 
innovative developments they are working on are to improve the health, disease burden or productivity of the 
animals themselves or to improve the quality of animal products; and the extent to which the animals themselves 
may present environmental hazards (this last being particularly relevant to insects and fish). 
5.2 Product and process based approaches 
The above analysis creates a case for regulatory consideration of each animal bio-science related innovation 
primarily on the basis of the nature of the product itself, and secondarily on the process by which it was 
developed. As noted above, for EU jurisdiction, were the existing GM crop regulatory system adopted as the 
relevant precedent for animal-related developments, a process-based approach would be likely. A recent EFSA 
review of its risk assessment processes for GMOs (Waigmann et al. 2012 p6), suggests that process-based 
regulation is not inevitable, however. In the context of the ‘product vs process’ debate, it was remarked that 
“[g]iven the fast development of new breeding/production technologies applied to organisms, which may need a 
revision of current regulatory definitions of genetic modification, EFSA is prepared to investigate risk 
assessment strategies for modified organisms, based on the characteristics of obtained products rather than based 
on the applied breeding/production technology.” If followed through, this could signal the beginning of a major 
shift in European regulatory systems as applied to GM and related technologies.  
5.3 Regulating a diversity of technological innovation 
Among the many functions of regulatory systems, a primary goal in the EU is reducing citizen exposure to 
hazards potentially posed by commercialised products and services. One view of regulation is that it serves 
innovators and the public best when it enables positive change in industry behaviour while carefully 
discriminating between types of risks that would be socially relevant (Mittra et al. 2011). Process-based 
regulations are indiscriminate when they apply equally to all GM organisms, irrespective of their properties, and 
product-based approaches do not discriminate among processes by which products are created. That much is 
tautological, but the salient point is that the principle goal of regulation is better met by considering the risks and 
benefits of product properties, for it is these that would be preferentially embraced or avoided by the public. 
Processes by which GM products are created are not benefits or risks in themselves.  
One example of how discriminating, enabling regulation might be applied to GM animals is the development of 
chickens resistant to avian influenza. Award of provisional regulatory approval in a restricted range of highly 
monitored circumstances could provide opportunities to gather evidence of the effectiveness, management 
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requirements and any unexpected side effects of the chickens, in a range of commercial situations. Such data 
could be usefully collected in advance of any crisis such as an influenza pandemic. The high potential for human 
benefit could justify ‘cautionary’ use of the technology in a restricted range of circumstances. 
In a second example, some might argue that genetic modifications deemed to be of welfare benefit could be 
given ‘fast track’ approval. Some beef cattle carry a natural genetic mutation and fail to develop horns (a state 
referred to as ‘polled’). This genetic variant rarely occurs in dairy cattle. A lack of horns is advantageous in 
terms of human safety when handling the cattle and of reducing the potential for cattle to harm each other. 
Current practice is to prevent the development of horns using chemical, heat or other methods, but the polled 
state could be produced by inducing a genetic change in the relevant gene using TALENs (Ridley 2013). If it is 
accepted that such changes would be beneficial to both animal and human welfare, then a ‘fast-track’ approval 
approach could be adopted for this innovation. 
Animal breeding activities currently are not subject to much regulation in the EU. Individual pedigree animals 
may be registered in herd books for quality assurance (the animal must be of the correct breed and have 
recognised parentage) or recorded in company databases. In many cases these records when combined with 
measurements on animals are essential for evaluation for genetic merit. Regulatory compliance tends to be 
restricted to those regulations pertaining to general agricultural practice such as animal welfare, environmental 
impact and animal disease control. Any regulatory process derived specifically for advanced biotechnology as 
applied to animals would require the current breeding industry to acquire new skills in regulatory compliance, 
but consideration should be given to which regulatory approaches would be most enabling of innovation.  
Managing the transition from first generation GM animals to more mature techniques and applications of 
genetic manipulation could provide an opportunity for developing a more discriminating regulatory framework 
that might influence the direction of innovation in GM animals. Whether the case for using GM animals to 
support sustainable intensification is accepted or not, innovation in the field of GM animal technologies is 
arguably far ahead of the policy and regulatory environment. Future regulation of GM animals should be 
capable of evolving as scientific and technical capacity expands and as lessons are learned about the most 
appropriate forms of regulation. This requires flexibility in the face of uncertainties around the eventual 
applications, products, processes and risks of GM animals.  
 
6 Conclusion 
Specific GM animal regulatory frameworks are yet to be developed, and in the meantime other existing 
regulations, guidances and practices are being adapted in response to the few attempts to commercialise GM 
animal technology. Costs, delays and uncertainties are all but guaranteed, and for the foreseeable future one can 
expect a negative, reinforcing cycle of lack of commercial products, few regulatory changes, lack of investment, 
policy ambivalence and shortfalls in research funding where socio-economic impact is less assured. At the same 
time, innovation in the life sciences is reflected in increasingly sophisticated and discriminating methods of 
producing GM animals raising questions about the appropriateness of regulations derived on the basis of older 
technologies. Furthermore, the international nature of innovation means that challenges to restrictive regulations 
may derive from other jurisdictions. The time is ripe for re-examining GM animal regulation in the EU and 
elsewhere. 
 
The lack of a network of organisations to provide impetus and vision for animal biotechnology innovation 
suggests that regulatory development is likely to be more difficult to achieve. Individual and groups of scientists 
have been effective in projecting visions of the future and individual companies have sought to realise some of 
these visions, but without a network of organisations providing an ‘innovation configuration,’ the absorptive 
capacity of the private sector remains untested.  
 
Evidence from other industry sectors, such as pharmaceutical, medical diagnostic and GM crops suggests 
regulatory regimes are very influential in the type of companies able to commercialise new technologies, and the 
type of products they are able to market. Given the diversity in the technologies currently being developed, 
product-based approaches to the regulation of animal biotechnology are more appropriate. 
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Figure 2. Emergence of new techniques for animal genetic modification 
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